Objective:
To evaluate the relationship between ellipsoid zone integrity and low-luminance deficit as markers of disease progression and treatment response in geographic atrophy.
Approach:
- Study Design: Post hoc analysis of the phase 3 GATHER2 trial, focusing on patients treated with avacincaptad pegol.
- Patient Evaluation: Patients were assessed based on baseline low-luminance deficit (LLD) and categorized into quartiles.
- Measurements: Partial and total ellipsoid zone (EZ) attenuation were measured alongside visual acuity metrics.
Key Findings:
- Ellipsoid zone integrity and low-luminance deficit moved in parallel, indicating their potential as complementary markers.
- Patients in the lowest LLD quartile had less partial or total EZ attenuation than those in the highest quartile.
- Avacincaptad pegol treatment reduced progression of partial EZ attenuation by approximately 62% with monthly dosing and 67% with every-other-month dosing in the highest LLD quartile, and total EZ attenuation by approximately 31% with either dosing schedule.
Interpretation:
Limitations:
- The analysis is post hoc and may not establish causation.
- Results are specific to the GATHER2 trial population and may not generalize to all geographic atrophy patients.
Conclusion:
Sources:
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.